Aveo will soon find out whether Fotivda has a future, while Glaxo awaits data with an even longer-lasting HIV doublet.
As the plot thickens around the trigger for Aveo’s equity raise, the EU regulator considers pulling the group's renal cancer drug from the market.
The company emerges as the worst-performing stock after Europe’s most important cancer conference, which claims numerous other victims.
Most drugs get the nod in the US before Europe – but there are some cases where the usual trend is reversed.
After the recent EU positive opinion for Aveo's tivozanib, EP Vantage takes a look at other projects approved in the EU, but not the US.